| Methods |
2‐week placebo run‐in; inclusion criteria= mean sitting DBP 95‐110 mm Hg; 6‐week double‐blind treatment |
| Participants |
Fosinopril 20 mg: n=16(4 males,12 females); mean age=56.4(8.1) years; baseline sitting SBP=151.8(14.0) mm Hg, DBP=100.8(4.8) mm Hg, HR=75.9(11.9) bpm;
Placebo: n=18(2 males,15 females); mean age=53.2(7.0) years; baseline sitting SBP=160.1(22.1) mm Hg, DBP=100.1(2.4) mm Hg, HR=72.3(6.1) bpm |
| Interventions |
Fosinopril 20 mg once daily;
Placebo |
| Outcomes |
Trough sitting SBP/DBP;
Trough HR;
WDAE |
| Notes |
SBP change not reported, DBP change reported; SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from text, p. 496 and p. 460; BP measurement device not reported; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
